Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review

Michelle H. Chen1,2 · Yael Goverover1,3 · Helen M. Genova1,2 · John DeLuca1,2

Published online: 2 May 2020 © The Author(s) 2020

Abstract

Introduction Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well understood.

Objectives The current systematic review aimed to evaluate the efficacy of pharmacologic treatments for improving cognitive function among persons with MS.

Methods A literature search was conducted through the PubMed and PsycINFO databases. Two independent reviewers assessed each paper, and a third reviewer weighed in if the two reviewers could not reach a consensus. Classification of evidence was determined using the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials. Standardized effect sizes (Cohen’s $d$) were calculated to compare across studies.

Results Eighty-seven journal articles published between 1990 and January 2020 were included in the current review. Overall, there is insufficient evidence to support the use of pharmacologic treatments to improve cognitive function in persons with MS. There were many contradictory findings observed in this review, which may be due to possible unidentified moderating treatment response variables and/or lack of standardization in assessment procedures. There was also an overreliance on statistical significance (most papers did not provide sizes of treatment effects), which may not be clinically meaningful.

Conclusions Higher-quality randomized controlled trials are needed to establish the cognitive efficacy of pharmacologic treatments for MS-related cognitive dysfunction, with cognition as the primary endpoint. Researchers are urged to use standardized criteria (such as the AAN criteria) to guide their research designs. Clinicians should consider effect sizes of studies before deciding whether to prescribe certain medications to ameliorate cognitive symptoms.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40263-020-00734-4) contains supplementary material, which is available to authorized users.

1 Introduction

Multiple sclerosis (MS) is a progressive, autoimmune, inflammatory disease that affects myelination and axonal integrity in the central nervous system. Cognitive impairment occurs in approximately two-thirds of persons with MS [1, 2], most prominently in the domains of speed of information processing and learning and memory [2, 3]. Cognitive impairment can be extremely disruptive in symptom management, medication adherence, instrumental activities of daily living (e.g. managing finances, driving), employment, and independence among persons with MS [3–5]. Various medications have shown efficacy in reducing annualized relapse rates [6], brain lesions as detected by magnetic resonance imaging [7], and disability progression as determined by the Expanded Disability Status Scale [8] among persons with MS; however, these metrics do not account for the hidden disabling symptoms of MS, such as fatigue and cognitive impairment. Moreover, cognitive endpoints traditionally have not been incorporated into phase III MS pharmaceutical trials, and, if they are, they are typically not primary endpoints. This results in studies that are underpowered and/or poorly designed for the purpose of examining cognitive outcomes. Therefore, our knowledge base regarding the...
The current review examines the usefulness of pharmacologic treatments on improving cognitive function in persons with multiple sclerosis (MS).

In conclusion, there is insufficient evidence to support the use of pharmacologic intervention to improve cognitive function in persons with MS.

Higher-quality randomized controlled trials are needed to establish the cognitive efficacy of pharmacologic treatments for MS-related cognitive dysfunction, with cognition as the primary endpoint. Researchers are urged to use standardized criteria (such as the American Academy of Neurology criteria) to guide their research designs.

Clinicians should consider effect sizes of studies before deciding whether to prescribe certain medications to ameliorate cognitive symptoms.

The current review examines the usefulness of pharmacologic treatments on improving cognitive function in persons with MS is limited.

There is currently no standard intervention for cognitive impairment in MS, although research has been conducted investigating various pharmacologic, behavioral, and brain stimulation treatments. Specifically regarding medications, a 2013 Cochrane Review concluded that there is “no convincing evidence to support the efficacy of pharmacological symptomatic treatment for MS-associated memory disorder” due to the poor quality of extant literature [9]. A more recent review published in 2016 similarly outlined methodological problems in pharmaceutical trials but argued that newer disease-modifying therapies (DMTs) and certain symptomatic therapies show promise in benefitting cognitive function [10]. Both articles included only randomized controlled trials (RCTs), which are the gold standard in evaluating therapeutic effects. Neither article recommended any medication for standard clinical use of improving cognitive function due to the limitation of available evidence.

The current systematic review aimed to evaluate the efficacy of pharmacologic treatments in improving cognitive function among persons with MS, using the American Academy of Neurology (AAN) classification of evidence criteria and standardized effect size measures (when possible) for comparison across studies. Given the lack of established standard pharmacologic treatment for cognitive impairment in MS, and limited research base in general, we included all medications that were the subject of cognitive efficacy investigation in persons with MS, in order to present a comprehensive overview of the literature. Although the current review focused primarily on RCTs in establishing conclusions regarding various medications, a brief discussion of all relevant studies (including non-RCTs) was also included to address limitations of the literature as a whole.

2 Methods

A literature search was conducted of the PubMed and PsycINFO databases, using the following keywords: cognition, cognitive, neuropsychological, multiple sclerosis, disease modifying therapy, drug, medication, processing speed, attention, working memory, executive functioning, learning, and memory. Additionally, to identify abstracts that may not explicitly refer to cognition, particularly in studies where cognition is not the primary endpoint, ‘PASAT’ and ‘SDMT’ were used as keywords as they are the most commonly used tests in these studies [11]. Only original, English-language research articles published in peer-reviewed journals between 1990 and January 2020 with human adult subjects were included in the current review. To be included, studies had to utilize at least one objective measure of cognition; studies using only subjective reports of cognition were excluded. Case studies, editorials, book chapters, and review articles were excluded, although citations in book chapters and review articles were cross-referenced and relevant articles were extracted. The initial search yielded 141 articles; 95 articles were screened based on the aforementioned inclusion and exclusion criteria, and a final sample of 87 articles were selected for final review (see Fig. 1).

Classification of evidence was determined using the 2017 AAN criteria for therapeutic trials [12] (see electronic supplementary Table 1 for criteria). Four study authors reviewed the final sample of 87 articles using a structured review table and criteria. Each article was independently assessed by two reviewers who rated the article’s classification of evidence. For each article, if there was disagreement, the two reviewers discussed their rationales and reached a consensus. If no consensus was reached, a third reviewer was asked to weigh in. Cohen’s $d$ was calculated as the measure of standardized effect size using a web calculator (https://www.psycometrika.de/effect_size.html) for RCTs and controlled studies. Effect sizes were only calculated for positive studies (i.e., studies indicating significant treatment effects). For studies that provided Cohen’s $g$, the provided values were included in this review. For studies with unbalanced groups, we used modules #2 and #3 in the web calculator (analogous to Hedges’ $g$), which corrected for the unequal sample sizes among groups. For small sample sizes (total sample size in both groups $n < 50$), we multiplied the effect sizes by the bias correction factor $(n−3)/(n−2.25)\times\sqrt{n−2}/n$. Data were treated parametrically, even in studies that utilized non-parametric tests (e.g. Wilcoxon signed-rank test) due to the lack of test statistics presented in most of these studies required to calculate
non-parametric effect sizes. Repeated measures (e.g. pre- and post-treatment) were treated as independent measures (using module #3 in the web calculator) because most studies did not provide correlation between pre- and post-treatment values, as was needed to account for repeated measure effects; calculation of Cohen’s $d$ based on the methods established by Morris and DeShon [13, 14] was used in these cases. Some studies did not provide sufficient information to calculate effect sizes, including studies that did not provide means and standard deviations (SDs) and studies that only provided medians and ranges/confidence intervals. Therefore, no effect sizes were provided for these studies.

3 Results

Eighty-seven articles published between 1990 and January 2020 were included in this review. For classification of evidence using the AAN criteria, reviewers disagreed on 31 articles, of which they were able to reach a consensus after discussion on 30 articles, and a third reviewer weighed in for one article. The medications were divided into three categories for the purpose of this review: DMTs, symptomatic therapies, and other therapies. The efficacy of these medications on cognitive function was reviewed. For brevity, this review analyzed only the primary cognitive endpoints if the studies specified them. A study was considered negative if the treatment effect was found on a secondary endpoint but not a primary endpoint. If primary endpoints were not specified, all cognitive endpoints were analyzed; however, the lack of a primary endpoint specification would be noted as a weakness, which would downgrade the AAN classification of evidence. Secondary analyses of RCTs that only included a subset of the original treatment allocation groups were designated as class III due to increased participant selection bias (i.e. not all participants had equal opportunity to be allocated to each group). As a general trend, the proportion of positive studies (i.e. findings of significant drug efficacy) tended to increase as the quality of evidence (AAN classifications) decreased. Indeed, class IV observational studies consisted of the highest number of positive studies (number of positive studies: class IV = 33; class III = 24; class II = 24; class I = 6) (see Fig. 2). The following sections discuss each medication in detail individually, with an emphasis on RCTs. Tables 1, 2, 3, 4, 5 and 6 summarize the main findings, effect sizes, and evidence classifications of the studies reviewed. Data are divided into RCTs (Tables 1, 2, 3), non-randomized, controlled/quasi-controlled studies (Table 4), and observational studies (Tables 5, 6).

Fig. 1 Study selection process

Records identified through database search of titles and abstracts (n = 141)

Excluded: 46 studies

Reasons for exclusion:
Did not include an objective cognitive outcome (n = 29)
Not on drug efficacy (n = 10)
Reviews or commentaries (n = 7)

Full texts retrieved and assessed for eligibility (n = 95)

Excluded: 8 studies

Reasons for exclusion:
On same trial with no additional information (n = 2)
Duplicate (n = 1)
Results not included (n = 2)
Trial halted early due to side effects (n = 1)
Drug produced delirium (n = 1)

Publications meeting inclusion and exclusion criteria (n = 87)

△ Adis
| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|-----------------------------|-----------------------------------|---------------|-----------------------------------|------------------|----------|
| **IFNs β-1a and 1b** | | | | | | | |
| Mokhber et al. (2014) [15] | 63 RRMS patients (comparators = IFNs β-1a and 1b) | BRNB | Yes | IFN β-1a (Avonex and Rebif) groups significantly improved on more measures (six and five of eight, respectively) than the IFN β-1b (Betaferon) group (one of eight) after 1 year | Compared with Betaferon, Cohen’s \( d = 0.04-0.25 \) for Avonex and \( 0.02-0.36 \) for Rebif (mean = 0.16) | Class II | More than two primary endpoints |
| **IFN β-1a** | | | | | | | |
| Cohen et al. (2002) [17] | 436 SPMS patients (comparator = placebo) | PASAT | No | Trend of improvement after 2 years of treatment relative to the placebo group | Cohen’s \( d = 0.20 \) | Class II | IMPACT trial; met class I criteria but downgraded because cognition was not the sole primary endpoint |
| **IFN β-1b** | | | | | | | |
| Montalban et al. (2009) [21] | 73 primary or transitional progressive MS patients (comparator = placebo) | BRNB | No | No significant differences between groups after 2 years of treatment | NA | Class II | Unclear if allocation was concealed |
| Penner et al. (2012) [22] | 439 originally CIS patients (comparator = placebo) | PASAT | No | RCT phase: Significant improvement after 2 years of treatment relative to the placebo group | Cohen’s \( d = 0.23 \) at year 2 Cohen’s \( d = 0.32 \) at year 5 | Class II | BENEFIT trial; secondary analysis of a previous study that did not a priori define cognitive endpoints |
| **Glatiramer acetate** | | | | | | | |
| Weinstein et al. (1999) [26] | 248 RRMS patients (comparator = placebo) | BRNB | No | No significant treatment effect after 24 months | NA | Class II | Secondary analysis of previous study that did not a priori define cognitive endpoints; current study did not specify primary endpoints |
### Table 1 (continued)

| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|----------------------------|-------------------------------------|--------------|-----------------------------------|-------------------|----------|
| **Fingolimod** | | | | | | | |
| Kappos et al. (2016) [45] | 1556 RRMS patients (subset of original trials: lower-dose vs. placebo groups)—first 6 months of data (comparator = placebo) | PASAT | No | Significant improvement after 6 months of treatment relative to the placebo group | Cohen’s $d = 0.13$ | Class II | FREEDOMS and FREEDOMS II trials; secondary analysis of a previous study that did not a priori define cognitive endpoints |
| Comi et al. (2017) [46] | 157 RRMS patients with $\geq 1$ test of BRNB of scores $<10$th percentile (comparator = IFN β-1b) | BRNB and D-KEFS Sorting Test | Primary endpoint not specified | No significant differences between groups after 18 months of treatment | NA | Class III | Open-label, rater-blinded GOLDEN trial; authors noted an imbalance in baseline characteristics and dropout pattern may have favored the comparator group |
| **Daclizumab β** | | | | | | | |
| Benedict et al. (2018) [47] | 1841 RRMS patients (comparator = IFN β-1a) | SDMT | No | Significant improvement but negligible treatment effect relative to the IFN group after 96 and 144 weeks | Cohen’s $d = 0.11$ at week 96; week 144 data were omitted because they were only 33% of the originally randomized sample | Class II | DECIDE trial; secondary analysis of RCT that did not a priori define cognitive endpoints; drug discontinued by drug companies due to reports of encephalitis in Europe |

Effect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g., immediate recall, delayed recall, and recognition of a memory test).

*AAAN* American Academy of Neurology, *BRNB* Brief Repeatable Neuropsychological Battery, *CIS* clinically isolated syndrome, *D-KEFS* Delis–Kaplan Executive Function System, *IFN* interferon, *MS* multiple sclerosis, *NA* not available, *PASAT* Paced Auditory Serial Addition Test, *RCT* randomized controlled trial, *RRMS* relapsing-remitting multiple sclerosis, *SDMT* Symbol Digit Modalities Test, *SPMS* secondary-progressive multiple sclerosis.
3.1 Disease-Modifying Therapies (DMTs)

Disease-modifying therapies are injectable or oral medications designed to prevent relapses and slow down the progression of MS. Various DMTs have different mechanisms of action, but most are immunosuppressive or immunomodulatory.

3.1.1 Interferon β-1a and Interferon β-1b

Seventeen studies examined the effects of interferon (IFN) β-1a and IFN β-1b, of which four were RCTs. Two studies compared IFNs β-1a and -1b, four studies examined IFN β-1a only, and 11 studies examined IFN β-1b only. Of 13 non-RCTs, five were class III controlled studies and eight were class IV observational studies. Only eight of all 17 studies investigated cognition as the primary endpoints, of which all but one were class III and IV.

Among studies comparing IFNs β-1a and -1b, one small class II RCT compared two IFN β-1a groups (Avonex and Rebif) with one IFN β-1b group (Betaferon) among 63 relapsing-remitting (RR) MS patients (21 per group) [15]. The IFN β-1a groups significantly improved on more neuropsychological measures than the IFN β-1b group [five and six of eight versus one of eight measures on the Brief Repeatable Neuropsychological Battery (BRNB)] after 1 year of treatment [15]. However, because the study included more than two primary measures (in fact, there were eight measures), the chances of type I error (i.e. false positive rate) were considerably increased. When we directly calculated and compared the effect sizes of IFN β-1a with IFN β-1b across the five and six statistically significant measures, they were small to negligible (Cohen’s $d=0.04$–$0.25$ for Avonex, and Cohen’s $d=0.02$–$0.36$ for Rebif, compared with Betaferon). A class III non-randomized, controlled study found no significant differences between the IFN β-1a and IFN β-1b groups [16].

In studies evaluating the cognitive effect of IFN β-1a relative to placebo, a class II RCT was conducted among 436 secondary-progressive MS patients, of which researchers of the IMPACT trial found a statistical trend of improvement (small effect: Cohen’s $d=0.20$) on the Paced Auditory Serial Addition Test (PASAT) over 2 years in the treatment group relative to the placebo group [17]. Of note, although Cohen et al. met all criteria for class I evidence, its classification was designated as class II because cognition was not the sole primary endpoint [17]. Therefore, these findings would need to be replicated in studies specifically targeting cognition. A class III secondary analysis of a larger RCT found a significant treatment effect [18], and two class IV observational studies favored high-dose (44 µg) over low-dose (22 µg) IFN β-1a treatment [19, 20].

In studies examining the cognitive efficacy of IFN β-1b relative to placebo, a class II RCT conducted in 73 primary/transitional progressive MS patients found no significant treatment effect over placebo on the BRNB over 2 years [21]; however, it was unclear whether allocation was concealed in this study. A class II secondary report of the
| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|----------------------------|-----------------------------------|--------------|----------------------------------|-------------------|----------|
| **Dalfampridine** | | | | | | |
| De Giglio et al. (2019) [48] | 120 MS patients with an SDMT score < 10th percentile (comparator = placebo) | SDMT | Yes | Significant improvement after 12 weeks of treatment relative to the placebo group; no significant difference between groups at 4-week follow-up (washout period) | Cohen's $d = 0.60$ for raw scores; Cohen's $d = 0.61$ for $z$ scores | Class I | |
| Arreola-Mora et al. (2019) [49] | 21 RRMS patients (comparator = placebo) | Study-specific neuropsychological battery | Yes | Significant improvement after 20 weeks of treatment relative to the placebo group, on 12 of 35 measures | Cohen's $d = 0.18$–$0.46$ (mean $= 0.38$) | Class II | Did not specify the primary endpoints |
| Satchidanand et al. (2020) [50] | 57 MS patients with at least 1.5 SD below the mean on one domain or informant report of cognitive impairment | SDMT | Yes | No significant treatment effect on SDMT relative to placebo after 12 weeks; responders improved on one of the secondary endpoints PASAT but not the primary endpoint SDMT | NA | Class II | No description regarding determination of cognitive impairment using objective measures or a randomization/blinding procedure |
| Broicher et al. (2018) [51] | 20 MS patients completed the crossover RCT phase (comparator = placebo); 2 weeks for each condition (2-week washout period) | Study-specific neuropsychological battery | | | Insufficient data | Class III | FAMPKIN extension trial; did not compare baseline characteristics between treatment order groups, or examine carryover effects; study authors classified the study as class II |
| Smits et al. (1994) [52] | 20 MS patients (crossover; comparator = placebo); 2 weeks for each condition (2-week washout period) | BRNB, computerized test adapted from CVLT | Yes | | NA | Class III | Treatment/placebo group had higher EDSS and lower SDMT than the placebo/treatment group at baseline; more than two primary endpoints specified |
| Authors (year) | $N$ | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|-----|---------------------------|-----------------------------------|---------------|-----------------------------------|------------------|----------|
| **Donepezil** |     |                           |                                   |               |                                   |                  |          |
| Krupp et al. (2004) [59] | 68 MS patients with an RAVLT score at least 0.5 SD below the mean, but an MMSE score ≥ 26 (comparator = placebo) | SRT total recall | Yes | Significant improvement after 24 weeks of treatment relative to placebo | Cohen’s $d = 0.50^a$ | Class I |          |
| Krupp et al. (2011) [60] | 120 MS patients with an RAVLT score at least 0.5 SD below the mean (comparator = placebo) | SRT total recall | Yes | No significant treatment effect after 24 weeks | NA | Class I |          |
| **Rivastigmine** |     |                           |                                   |               |                                   |                  |          |
| Shaygannejad et al. (2008) [61] | 60 MS patients with at least mild verbal memory impairment as indicated by the WMS (comparator = placebo) | WMS general memory score | Yes | No significant treatment effect after 12 weeks | NA | Class I |          |
| Huolman et al. (2011) [62] | 15 MS patients (comparator = placebo) | Modified PASAT for fMRI | No | Significant improvement relative to the placebo group | Cohen’s $d = 0.25$ | Class II | Did not specify the primary endpoint |
| Mäurer et al. (2013) [63] | 81 MS patients with a Faces Symbol Test score ≥ 3 and/or Multiple Sclerosis Inventory Cognition score ≤ 19 (comparator = placebo) | SRT | Yes | No significant treatment effect after 16 weeks | NA | Class II | Initially planned to recruit 200 patients but were only able to recruit 86 patients; changes made after randomization regarding eligibility criteria, sample size, and duration of follow-up |
### Table 2 (continued)

| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|-----------------------------|-----------------------------------|--------------|-----------------------------------|-------------------|----------|
| Cader et al. (2009) [64] | 15 MS patients with subjective cognitive complaints; crossover (treatment = rivastigmine + domperidone; comparator = domperidone); no washout period | BRNB | No | No significant treatment effect after 4 weeks | NA | Class III | Investigator-blind; baseline characteristics were not presented; 71% of enrolled participants completed the study |

**Memantine**

| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|-----------------------------|-----------------------------------|--------------|-----------------------------------|-------------------|----------|
| Saint Paul et al. (2016) [66] | 62 RRMS patients with a Dementia Rating Scale score ≥ 130 and PASAT > 15, but 1.5 SD below the mean (comparator = placebo) | PASAT | Yes | No significant treatment effect after 52 weeks | NA | Class II | EMERITE trial; only 67% of participants completed the study; discontinued participants were younger and had a better baseline PASAT score |
| Lovera et al. (2010) [65] | 114 MS patients with a PASAT or CVLT-II long-delay free recall of at least 1 SD below the mean (comparator = placebo) | PASAT, CVLT-II long-delay free recall | Yes | No significant treatment effect after 16 weeks | NA | Class III | Treatment group had a higher proportion of progressive subtypes and lower baseline CVLT-II score |

**Gingko biloba**

| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|-----------------------------|-----------------------------------|--------------|-----------------------------------|-------------------|----------|
| Lovera et al. (2007) [68] | 38 MS patients with a PASAT or CVLT-II total score 0.5–2.5 SD below the mean (comparator = placebo) | Study-specific neuropsychological battery | Yes | No significant treatment effect after 12 weeks | NA | Class II | More than two primary endpoints specified |
| Lovera et al. (2012) [67] | 120 MS patients with scores of 1 SD below the mean on the Stroop test, CVLT-II, COWAT, and PASAT (comparator = placebo) | Study-specific neuropsychological battery | Yes | No significant treatment effect after 12 weeks | NA | Class II | More than two primary endpoints specified; authors classified the study as class I |
| Authors (year)               | $N$                                      | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings                                                                 | Effect sizes for positive measures | AAN classification | Comments                                                                                                                                                                                                 |
|-----------------------------|------------------------------------------|----------------------------|-----------------------------------|-------------------------------------------------------------------------------|-----------------------------------|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Diamond et al. (2013)       | 21 MS patients (comparator=placebo)      | Study-specific neuropsychological battery | No                                | Significantly faster processing speed and fewer intrusions on verbal learning after 4 weeks of treatment relative to the placebo group (unclear how many total measures were examined due to limited content in the short report) | Cohen's $d=0.55$ for speed and Cohen's $d=0.78$ for intrusions | Class III         | Secondary analysis of a previous study that did not a priori define cognitive endpoints; more than two primary endpoints were specified in the current study; limited description of study procedures and results due to the short report format |
| Morrow et al. (2009)        | 136 MS patients with an SDMT 1.5 SD below the mean or CVLT-II total or delayed recall or PASAT 1 SD below the mean (comparator=placebo) | SDMT                        | Yes                               | No significant treatment effect after 29 days, on the SDMT; significant treatment effect on secondary measures of BVMT-R and CVLT-II delayed recall | NA                                | Class I           |                                                                                                                                                                                                           |
| Sumowski et al. (2011)      | 136 MS patients (comparator=placebo)    | CVLT-II and BVMT-R delayed recall | Yes                               | Significant improvement in baseline-impaired patients treated with l-amphetamine for 29 days, relative to the placebo and baseline-intact groups, on CVLT-II and BVMT-R (impairment based on median split) | Treatment—placebo, Cohen's $d=0.94$ for CVLT-II and $d=1.00$ for BVMT-R among baseline-impaired | Class II          | Re-analysis of the Morrow et al. study [70] (see Table 3); original study did not target memory-impaired participants                                                                                     |
| Benedict et al. (2008)      | 19 MS patients with CVLT-II, SDMT, or PASAT 1 SD below the mean (crossover; comparator=placebo); single dose of 15, 30, or 45 mg (1-week washout period) | Study-specific neuropsychological battery | Yes                               | Significantly better performance on processing speed measures under 45 mg treatment compared with placebo conditions; no significant findings for memory measures | Cohen's $d=0.36$–0.45 (mean=0.41) | Class III         | Did not compare baseline characteristics of the treatment order groups or examine carryover effects; more than two primary outcomes                                                                         |

**l-Amphetamine sulfate**

- **Diamond et al. (2013)**
- **Morrow et al. (2009)**
- **Sumowski et al. (2011)**
- **Benedict et al. (2008)**
| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|---------------------------|-----------------------------------|---------------|-----------------------------------|-------------------|----------|
| **Mixed amphetamine salts containing dextroamphetamine, amphetamine, d-amphetamine, and d-l-amphetamine aspartate monohydrate** | | | | | | | |
| Morrow and Rosehart (2015) [73] | 49 MS patients with scores of 1.5 SD below the mean on SDMT or PASAT (comparator = placebo); single dose of 5 or 10 mg | SDMT, PASAT | Yes | Significant improvement on SDMT after a single dose of 10 mg relative to placebo | Cohen’s $d = 0.47^a$ | Class I | |
| **Methylphenidate** | | | | | | | |
| Harel et al. (2009) [75] | 26 RRMS patients with PASAT < 25th percentile (comparator = placebo) | PASAT | Yes | Significant improvement after a single dose of drug relative to the placebo group | Cohen’s $d = 0.52$ for 3″ and $d = 0.71$ for 2″ | Class II | The authors did not provide detailed information about randomization and blinding (unclear about concealed allocation) |
| **Lisdexamfetamine dimesylate** | | | | | | | |
| Morrow et al. (2013) [74] | 63 MS patients with SDMT or PASAT 1.5 SD below the mean (comparator = placebo) | SDMT, PASAT | Yes | Significant improvement on SDMT after 4 weeks of treatment up to the highest tolerable dose relative to placebo group; SDMT score remained stable for another 4 weeks of treatment; no significant findings for PASAT | Cohen’s $d = 0.60$ | Class II | The treatment group had lower SDMT and BVMT-R scores at baseline, not controlled in the analyses; 76% dropout rate |
| **Modafinil** | | | | | | | |
| Möller et al. (2011) [76] | 121 MS patients with a Fatigue Severity Scale score ≥ 4 | SDMT, PASAT | No | Contradictory findings that did not favor one group | NA | Class II | Did not provide detailed information regarding blinding |
| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|---------------|---|---------------------------|----------------------------------|---------------|----------------------------------|------------------|----------|
| Ford-Johnson et al. (2016) [77] | 16 MS patients with a score of 1.5 SD below the mean on Open-Trial SRT (crossover; comparator = placebo); 2 weeks for each condition (1-week washout period) | CVLT-II | Yes | No significant change on CVLT-II; significant improvement relative to placebo on one of six secondary outcomes (of 11 measures in total) | NA | Class II | Given significant carryover effects, only between-subject analysis of the first 2 weeks of data was included; more than two primary outcomes |
| Bruce et al. (2012) [78] | 30 MS patients with an SDMT score 1 SD below the mean (crossover; comparator = placebo); single dose (1-week washout period) | Study-specific neuropsychological battery | Yes | Significant improvement on one of eight measures: RAVLT delayed recall | Cohen's $d = 1.33$ | Class II | Did not specify primary outcomes |
| Sailer et al. (2000) [80] | 24 MS patients with a Fatigue Severity Scale score $>4$ (crossover; comparator = placebo; 10-day washout period) | Reaction time task | No | No significant treatment effect relative to placebo condition after 10 days | NA | Class III | No details about dropouts; no direct comparison of treatment order groups for baseline measures; two treatment order groups differed in the main efficacy analysis |

Effect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their “Results” sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test)

AAN American Academy of Neurology, BRNB Brief Repeatable Neuropsychological Battery, BVMTR Brief Visual Memory Test, COWAT Controlled Oral Word Association Test, CVLT California Verbal Learning Test, CVLT-II California Verbal Learning Test, 2nd Edition, EDSS Expanded Disability Status Scale, fMRI functional magnetic resonance imaging, MMSE Mini-Mental State Examination, MS multiple sclerosis, NA not available, PASAT Paced Auditory Serial Addition Test, RAVLT Rey Auditory Verbal Learning Test, RCT randomized controlled trial, RRMS relapsing-remitting multiple sclerosis, SD standard deviation, SDMT Symbol Digit Modalities Test, SRT Selective Reminding Test, WMS Wechsler Memory Scale

\(^a\) Effect sizes provided by the study authors
### Table 3  Summary of RCTs for other treatments

| Authors (year) | N | Primary cognitive outcomes | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | AAN classification | Comments |
|----------------|----------------|---------------------------|------------------------------------|---------------|------------------------------------|-------------------|----------|
| **Recombinant human erythropoietin (EPO)** | | | | | | | |
| Schreiber et al. (2017) [82] | 50 progressive MS patients (comparator = placebo) | TMT Part B | No | No significant differences between groups after 24 weeks | NA | Class II | Met the class I criteria but downgraded because cognition was not the sole primary outcome |
| Ehrenreich et al. (2007) [95] | Eight chronic progressive MS patients who previously did not respond to DMTs: 5 in the high-dose group (48,000 IU) and three in the low-dose group (8000 IU) | Study-specific neuropsychological battery | Primary endpoint not specified | The high-dose group significantly improved on 7 of 13 measures after 24 weeks of treatment; the low-dose group did not improve over 12 weeks of treatment | From the table in the electronic supplementary material, at 12 weeks, treatment effect (high-dose vs. low-dose): Cohen’s $d = -0.063$ to $2.012$ (mean = 0.82) | Class IV | Open-label; authors did not directly compare the high-dose and low-dose groups after 12 weeks of treatment (last time point when data were available for both groups); no inclusion of baseline comparison between the groups |
| **Simvastatin** | | | | | | | |
| Chan et al. (2017) [83] | 140 SPMS patients not treated with DMTs (comparator = placebo) | Study-specific neuropsychological battery | No | Significant improvement after 24 months of treatment compared with placebo on one screening measure of 15 total measures | Insufficient data | Class II | MS-STAT trial; study did not specify the primary outcomes |
| **Atorvastatin** | | | | | | | |
| Lanzillo et al. (2016) [84] | 154 RRMS patients (comparator = placebo) | BRNB | No | No significant treatment effect after 24 months | NA | Class II | Large dropout rate; only 63% of the original randomized patients were analyzed for cognitive data |
| **Estrogen** | | | | | | | |
| De Giglio et al. (2017) [85] | 142 female RRMS patients (comparators: IFN β-1a with 20 μg estrogen, IFN β-1a with 40 μg estrogen, or IFN β-1a) | BRNB: proportion of people with at least two test scores that were 1 SD below the mean | No | At month 24, the high-dose estrogen group had significantly fewer patients with cognitive impairment than the IFN-only group, and lower risk of developing cognitive impairment | Odds ratio for the high-dose estrogen group’s reduced risk of cognitive impairment = 0.27* | Class II | Did not specify the primary outcomes |

Effect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test).

AAN American Academy of Neurology, BRNB Brief Repeatable Neuropsychological Battery, DMTs disease-modifying therapies, IFN interferon, MS multiple sclerosis, NA not available, RCT randomized controlled trial, RRMS relapsing-remitting multiple sclerosis, SD standard deviation, SPMS secondary-progressive multiple sclerosis, TMT Trail-Making Test

*Effect sizes provided by the study authors
| Authors (year) | N                   | Primary cognitive outcome | Cognition as the primary endpoint? | Main findings                                                                 | Effect sizes for positive measures | Comments                                                                 |
|---------------|---------------------|---------------------------|-----------------------------------|-------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------|
| **Disease-modifying therapies** | | | | | | |
| **IFNs β-1a and 1b** | | | | | | |
| Melanson et al. (2010) [16] | 40 RRMS patients (comparators = IFN β-1a and IFN β-1b) | BRNB | Yes (along with fatigue as the co-primary endpoint) | No significant differences among groups after 6 and 12 months of treatment | NA | |
| Fischer et al. (2000) [18] | 166 RRMS patients (comparator = placebo; part of a larger RCT) | Composite scores: (a) information processing and learning/memory; (b) visuospatial and problem-solving; (c) verbal and attention (guided by factor analysis) | No | Significant improvement after 2 years of treatment, on information processing and learning/memory | Insufficient data | |
| **IFN β-1b** | | | | | | |
| Pliskin et al. (1996) [24] | 30 MS patients (comparator = placebo; part of a larger RCT) | Study-specific neuropsychological battery | No | Significant improvement in the high-dose treatment group over 2 years (year 2 to year 4) relative to other groups (low-dose and placebo) on 11 of 12 measures | High-dose: Cohen’s $d=0.59$ relative to the low-dose treatment group; $d=0.91$ relative to the placebo group | |
| Barak and Achiron (2002) [23] | 46 RRMS patients (comparator = untreated RRMS patients matched on the EDSS) | BRNB | Yes | Significant improvement in the treatment group after 1 year on three of six measures; significant decline on three of six measures in the comparator group | Treatment effect relative to the comparator group: Cohen’s $d=0.40$–8.05 (mean = 2.63) | Two groups had comparable performances at 1-year follow-up; treatment effects were driven by lower performance in the treatment group at baseline |
| Selby et al. (1998) [96] | 167 RRMS patients (comparator = waitlist) | Study-specific neuropsychological battery | Yes | No significant cross-sectional differences between groups | NA | |
| **Glatiramer acetate** | | | | | | |
| Vacarăş et al. (2014) [27] | 37 RRMS with 3–4 years disease course and drug-naive (comparator = placebo) | PASAT and MoCA | No | The treatment group significantly improved on PASAT after 1 year, while the placebo group significantly declined. The treatment group did not improve on MoCA, and the placebo group declined | Insufficient data | Did not note randomization or blinding |
| Authors (year) | N | Primary cognitive outcome | Cognition as the primary endpoint? | Main findings | Effect sizes for positive measures | Comments |
|--------------|---|--------------------------|----------------------------------|---------------|----------------------------------|----------|
| Ytterberg et al. (2007) [28] | 83 MS patients; all started with monotherapy (glatiramer acetate or IFN β); 21 patients switched to combination therapy (glatiramer acetate + IFN β) due to worsening of MS symptoms | SDMT | No | No significant differences between the monotherapy (glatiramer acetate or IFN β for 24 months) and combination therapy (glatiramer acetate and IFN β for 16–24 months) groups; did not compare between two monotherapy groups | NA | |
| Natalizumab | | | | | | |
| Weinstock-Guttman et al. (2012) [32] | 942 RRMS patients (comparator = placebo; part of a larger RCT) | Onset of 0.5 SD decline on PASAT sustained for 12 weeks | No | Significantly reduced risk of cognitive decline after 2 years relative to the placebo group in the AFFIRM trial; no significant reduction in the SENTINEL trial | Hazard ratio = 0.57\(^a\) | Results from the AFFIRM and SENTINEL trials; unclear if the two groups were matched |
| Rorsman et al. (2018) [35] | 34 RRMS patients with at least one measure of 2 SDs below the mean or two measures of 1 SD below the mean (comparator = stable MS patients receiving other DMTs) | MACFIMS | Yes | Between-subject: Significant improvement after 1 year of treatment relative to quasi-controls on PASAT (1 of 10 measures). Within-subject: Significant improvement in the treatment group on 4 of 10 measures, but not in quasi-controls | Insufficient data | Quasi-controls had higher SDMT scores and longer illness duration; a higher proportion of the natalizumab group had a relapse within the past 6 months, and lesions |
| Mattioli et al. (2011) [34] | 24 RRMS patients (comparator = stable MS patients taking other DMTs) | Study-specific neuropsychological battery | Yes | Between-subject: Significant improvement after 1 year of treatment, relative to the placebo group, on delayed visual memory composite (1 of 10 measures) Within-subject: Significant improvement in the treatment group on 3 of 10 measures, and no significant change in the quasi-comparator group | Insufficient data | The natalizumab group had significantly more relapses in the previous year than the quasi-comparator group |
| Sundgren et al. (2016) [97] | 30 RRMS patients (comparator = stable MS patients receiving other DMTs) | Study-specific neuropsychological battery | Yes | No significant differences between groups after 1 year of treatment | NA | The natalizumab group had significantly higher EDSS and non-significant higher disease duration than the quasi-comparator group |
Table 4 (continued)

| Authors (year)                              | N                          | Primary cognitive outcome                                                                 | Cognition as the primary endpoint? | Main findings                                                                 | Effect sizes for positive measures | Comments                                                                 |
|--------------------------------------------|-----------------------------|------------------------------------------------------------------------------------------|------------------------------------|-------------------------------------------------------------------------------|-----------------------------------|--------------------------------------------------------------------------|
| Iaffaldano et al. (2016) [36]              | 58 RRMS patients (comparator = patients who stopped treatment) | CII = as impaired; index based on the number of SDs below the mean on individual tests from the BRNB and Stroop test | Yes                                | Significant increase in CII among interrupters after 1 year of discontinuation, and decrease in continuers | Reduction of CII in continuers compared with interrupters: Cohen’s $d = -0.62$ |                                                                 |
| Mitoxantrone                               |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Schröder et al. (2011) [98]                | 26 progressive or relapsing-progressive MS patients (comparator = MS patients who met the criteria for therapy but did not receive treatment) | Study-specific neuropsychological battery                                                | Yes                                | No significant change in the treatment group after 2 years; the comparator group had reduced performance on two of seven measures | Insufficient data               | It was noted that the comparator group did not receive treatment due in part to cardiac contraindications; the comparator group was significantly smaller ($n = 6$) |
| Symptomatic treatments                     |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Modafinil                                  |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Lange et al. (2009) [79]                   | 21 MS patients with an FSS sum score ≥ 36 (comparator = placebo; part of a larger RCT) | d2 alertness test                                                                        | No                                 | Significant reduction in errors in the treatment group after 3 h and 8 weeks of treatment; no change in the placebo group | Insufficient data               |                                                                 |
| Amantadine                                 |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Geisler et al. (1996) [81]                 | 45 Ambulatory MS patients with FSS ≥ 4 (part of a larger RCT)                               | Study-specific neuropsychological battery                                                | No                                 | No significant differences among the amantadine, pemoline, or placebo groups after 6 weeks | NA                                | More than two primary outcomes specified                                |
| Other treatments                            |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Methylprednisolone                          |                             |                                                                                          |                                    |                                                                                |                                   |                                                                         |
| Patzold et al. (2002) [86]                 | 37 MS patients (comparators: 27 with acute exacerbation and 10 without acute exacerbation) | PASAT                                                                                    | No                                 | Significant improvement after 19 days of treatment; no significant change in the quasi-control group | Cohen’s $d = 0.36$               |                                                                 |

Effect sizes were only calculated for studies with positive findings; some effect sizes could not be calculated due to insufficient data provided in the papers. The total number of cognitive measures was determined by what the authors presented in their Results sections; multiple scores from a cognitive test count as multiple measures (e.g. immediate recall, delayed recall, and recognition of a memory test).

BRNB: Brief Repeatable Neuropsychological Battery, CII: Cognitive Impairment Index, DMTs: disease-modifying therapies, EDSS: Expanded Disability Status Scale, FSS: Fatigue Severity Scale, IFN: interferon, MACFIMS: Minimal Assessment of Cognitive Function in Multiple Sclerosis, MoCA: Montreal Cognitive Assessment, MS: multiple sclerosis, NA: not available, PASAT: Paced Auditory Serial Addition Test, RCT: randomized controlled trial, RRMS: relapsing-remitting multiple sclerosis, SD: standard deviation, SDMT: Symbol Digit Modalities Test

*Effect sizes provided by the study authors*
### Table 5  Summary of all other observational studies (class IV) for disease-modifying therapies

| Authors (year) | N                  | Primary cognitive outcome | Cognition as the primary endpoint? | Main findings                                                                 | Comments                                                                 |
|---------------|--------------------|---------------------------|-----------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| *IFN β-1a*    |                    |                           |                                   |                                                                               |                                                                          |
| Patti et al. (2010) [20] | 318 treatment-naive RRMS patients (comparators: 44 µg and 22 µg) | Proportion of patients with cognitive impairment (based on 1 SD below the mean on ≥ 3 tests of the BRNB and Stroop test) | Yes | 32% significant risk reduction in the 44 µg vs. 22 µg groups; the 44 µg group had a significantly lower risk of cognitive impairment at year 3 relative to 22 µg group | COGIMUS trial |
| Patti et al. (2013) [19] | 133 treatment-naive RRMS patients (comparators: 44 µg and 22 µg) | Proportion of patients with cognitive impairment (based on 1 SD below the mean on ≥ 3 tests of the BRNB and Stroop test) | Yes | The 44 µg group had a significantly lower risk of cognitive impairment than the 22 µg group | 2-Year extension study after the original COGIMUS trial; patients continued the same treatment dose |
| *IFN β-1b*    |                    |                           |                                   |                                                                               |                                                                          |
| Tur et al. (2011) [101] | 59 PPMS patients | BRNB | No | After 5 years without treatment, the original treatment group performed significantly better than the original placebo group, on one of six measures | Follow-up of the study by Montalban et al. [21] (placebo-controlled RCT; see Table 3) |
| Edan et al. (2014) [99] | 464 originally CIS patients; some converted to MS | PASAT | No | At year 8 (6 years after the double-blind phase ended), the early treatment group (previously in the treatment group) had a higher score increase than the delayed treatment group (previously in the placebo group) | Follow-up of BENEFIT (placebo-controlled RCT; see Penner et al. [22]; see Table 3) |
| Kappos et al. (2016) [100] | 278 originally CIS patients; some converted to MS | PASAT | No | At year 11 (9 years after the RCT ended), the early treatment group (previously in the treatment group) had a higher score increase than the delayed treatment group (previously in the placebo group) | Follow-up of BENEFIT (placebo-controlled RCT; see Penner et al. [22]; see Table 3) |
| Flechter et al. (2007) [25] | 15 MS patients | WCST perseverative response score | Yes | Significant improvement after 1 year | Follow-up of placebo-controlled RCT; study attributed stability of cognition to benefit of drug |
| Lacy et al. (2013) [103] | 16 RRMS patients | Study-specific neuropsychological battery | Yes | At year 16 relative to year 2, no consistent pattern of change in the overall cohort or previous treatment allocation groups | Follow-up of placebo-controlled RCT; study attributed stability of cognition to benefit of drug |
| Gerschlager et al. (2000) [102] | 14 MS patients treated with IFN, and 14 healthy participants | Study-specific neuropsychological battery | No | Similar pattern of improvement in MS patients and healthy participants after 1 year | Follow-up of placebo-controlled RCT; study attributed stability of cognition to benefit of drug |
Table 5 (continued)

| Authors (year) | N | Primary cognitive outcome | Cognition as the primary endpoint? | Main findings | Comments |
|---------------|---|--------------------------|-----------------------------------|---------------|----------|
| **Glatiramer acetate** | | | | | |
| Schiwed et al. (2007) [104] | 153 MS patients | BRNB | No | 10 Years after the RCT, no significant differences between the original treatment allocation groups | Follow-up of a placebo-controlled RCT |
| Ziemssen et al. (2014) [29] | 72 RRMS patients | PASAT | No | Significant improvement after 2 years of treatment | COPTIMIZE trial |
| Ziemssen et al. (2015) [31] | 668 RRMS patients | PASAT | No | Significant improvement after 2 years of treatment | COPTIMIZE trial |
| Ziemssen et al. (2016) [30] | MS patients (370 had PASAT data; 453 had MUSIC data) | PASAT and MUSIC scales | No | Significant improvement after 2 years of treatment | QualiCOP trial |
| **Natalizumab** | | | | | |
| Iaffaldano et al. (2012) [43] | 100 RRMS patients (53 completed 2 years) | CII based on the number of SDs below the mean on individual tests from the BRNB and Stroop test | Yes | Significant reduction of CII after 1 and 2 years of treatment | |
| Iaffaldano et al. (2014) [38] | 42 RRMS patients (21 completed 2 years) | CII based on the number of SDs below the mean on individual tests from the BRNB and Stroop test | Yes | Significant reduction of CII after 1 year of treatment; significant reduction of CII after 2 years of treatment | |
| Mattioli et al. (2011) [37] | 39 RRMS patients (11 with year 2 data) | Study-specific neuropsychological battery | Yes | Significant improvement after 1 and 2 years of treatment, on 3 of 13 measures (different three measures for each year; \( p < 0.001 \) to 0.048) | |
| Mattioli et al. (2015) [44] | 24 RRMS patients | Study-specific neuropsychological battery | Yes | Significant reduction in the number of impaired neuropsychological tests (2 SDs below the mean) over 3 years of treatment | |
| Wilken et al. (2013) [41] | 89 RRMS patients | Automated Neuropsychological Assessment Metrics | No | Significant improvement after 2 years of treatment, on two of three indices | ENER-G trial |
| Lang et al. (2012) [39] | 29 MS patients after other DMTs have failed | Study-specific neuropsychological battery | Primary endpoint not specified | Significant improvement on 3 of 14 measures over 6 months of treatment | |
| Perumal et al. (2019) [42] | RRMS patients with diagnosis <3 years (191 treated for 1 year; 158 treated for 2 years) | SDMT | No | Significant improvement on SDMT after 1 and 2 years of treatment | STRIVE trial |
BENEFIT trial found a significant but small treatment effect (Cohen’s $d = 0.23$) for IFN β-1b relative to placebo on the PASAT 2 years after the trial among 439 patients with clinically isolated syndrome [22]. Since the original BENEFIT trial was not designed to examine cognitive endpoints, these findings would need to be replicated in cognition-focused studies. Apart from observational follow-ups of the two class II RCTs described above, there were three class III studies (one was a secondary analysis of a larger RCT and two were non-randomized, controlled studies), two of which found significant treatment effects [23, 24]. Of the remaining three class IV observational studies without adequate comparator groups, only one was positive [25].

In sum, there was no class I evidence for the cognitive efficacy of IFN β-1a or IFN β-1b. Class II RCTs demonstrated small to negligible or no treatment effects. Studies of lower quality yielded mixed findings.

### 3.1.2 Glatiramer Acetate

Seven studies examined the cognitive efficacy of glatiramer acetate. Cognition was not the primary endpoint in any of these studies. Only one study was an RCT (class II), two were class III non-randomized, controlled studies, and four were observational studies without comparator groups. The class II RCT did not detect a significant improvement on the BRNB after 2 years of glatiramer acetate treatment over placebo among 248 RRMS patients [26]. Since this study was a secondary analysis of an RCT that did not a priori specify cognitive endpoints, it only met criteria for class II. The two class III studies yielded mixed results [27, 28], and three of four class IV studies were positive [29–31].

### 3.1.3 Natalizumab

There were no prospective RCTs that examined the cognitive efficacy of natalizumab. Five of 13 studies were class III (one was a secondary analysis of a subset of larger RCTs, and four were non-randomized, controlled studies), and the remainder were class IV observational studies without comparator groups. Cognition was the primary endpoint in 8 of 13 studies. The class III secondary analysis of the AFFIRM and SENTINEL RCTs among 942 RRMS patients (subsets of original trials) found a 43% reduced risk of declining 0.5 SDs on the PASAT score 2 years following natalizumab treatment, compared with placebo in the AFFIRM trial [32]. However, it is important to note that the threshold of 0.5 SDs may not represent a clinically significant decline; studies more typically use at least one SD as the threshold to document change [33]. Three of four remaining class III studies were positive (of which two studies only found significant effects on one of 10 measures) [34–36]. The eight class IV
| Authors (year)          | $N$                              | Primary cognitive outcome | Cognition as the primary endpoint? | Main findings                                                                 | Comments                                                                                         |
|------------------------|----------------------------------|---------------------------|-----------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| **Symptomatic treatments** |                                  |                           |                                    |                                                                               |                                                                                                  |
| **Dalfampridine**      |                                  |                           |                                    |                                                                               |                                                                                                  |
| Korsen et al. (2017) [53] | 34 MS patients with impaired mobility | PASAT                    | No primary endpoint specified      | Significant improvement for the entire cohort; responder status did not predict cognitive change |                                                                                                  |
| Triche et al. (2016) [55] | 39 MS patients newly prescribed dalfampridine: 31 were treated with drug for 14 weeks or longer, and 8 discontinued drug before 14 weeks | SDMT                     | No primary endpoint specified      | Significant improvement on SDMT in patients treated for at least 14 weeks, but only patients who were responders |                                                                                                  |
| Magnin et al. (2015) [54] | 50 MS patients                   | Letter fluency (“p”) and semantic (animal) fluency for 120" | Yes                               | Letter fluency significantly improved after 14 days and 21 days of treatment; semantic fluency significantly improved after 21 days of treatment; responder status did not predict cognitive change |                                                                                                  |
| Ruck et al. (2014) [57]  | 52 MS patients with impaired mobility (only 30 were still on drug after 9–12 months) | PASAT                    | No primary endpoint specified      | Significant improvement on the PASAT after 9–12 months of treatment          |                                                                                                  |
| Bakirtzis et al. (2018) [56] | 60 MS patients                   | BICAMS                    | No primary endpoint specified      | Significant improvement on SDMT after 6 months and 1 year of treatment for responders but not non-responders | IGNITE trial                                                                                     |
| Pavsic et al. (2015) [107] | 30 MS patients                   | PASAT                     | No primary endpoint specified      | No significant improvement after 14 or 28 days of treatment                  |                                                                                                  |
| Jensen et al. (2014) [58]  | 105 MS patients                  | SDMT                      | No                                 | Significant improvement after 26–28 days of treatment                       |                                                                                                  |
| **Donepezil**          |                                  |                           |                                    |                                                                               |                                                                                                  |
| Greene et al. (2000) [108] | 17 MS patients with MMSE $\leq 25$ at a long-term care facility | MMSE, HVLT               | Yes                               | Significant improvement after 4 and 12 weeks of treatment on MMSE and HVLT recognition hits; no differences on HVLT recall trials |                                                                                                  |
3.1.4 Fingolimod

Two studies examined the cognitive efficacy of fingolimod: one class II and one class III. Cognition was not the primary endpoint in either study. A class II pooled analysis of the FREEDOMS and FREEDOMS II RCTs showed significant improvement on the PASAT after the first 6 months of treatment over placebo in 1556 RRMS patients, with a negligible effect size (Cohen’s $d = 0.13$) [45]. The class III open-label (rater-blinded) GOLDEN RCT conducted in 157 cognitively impaired RRMS patients found no significant treatment effect of fingolimod over IFN β-1b after 18 months [46]. Of note, the authors stated that imbalance in baseline characteristics (i.e. disease severity and baseline cognitive test scores) and dropout pattern may have favored the IFN comparator group.

3.1.5 Other DMTs

Additionally, there were one class II, one class III, and two class IV studies for all other DMTs, only one of which was an RCT. Cognition was the primary endpoint in only one of four studies and not in the RCT. The class II RCT, the DECIDE trial conducted in 1841 RRMS patients, found a statistically significant but negligible treatment effect using daclizumab β for 96 weeks compared with IFN β-1a, on the Symbol Digit Modalities Test (SDMT), yielding a negligible effect size (Cohen’s $d = 0.11$) [47]. The study was classified as class II because there was no prespecification of cognitive endpoints in the original trial, as required by AAN criteria. Of note, daclizumab β has been discontinued by pharmaceutical companies due to reports of encephalitis in Europe.

3.1.6 Summary

In sum, there is a paucity of good-quality evidence in support of the cognitive efficacy of DMTs in persons with MS. There was no class I evidence for this drug type, and the majority of studies were class III and IV. Class II investigations either showed small/negligible or no significant treatment effects. Although many class III and IV observational studies yielded positive results (particularly for natalizumab), these studies suffered from a myriad of methodological limitations (e.g. absence of randomization or equivalent comparator groups, more than two primary cognitive endpoints), which restricts generalizable validity. Therefore, at this time, there is insufficient evidence to support the use of DMTs to improve cognitive function in persons with MS.
3.2 Symptomatic Therapies

Symptomatic therapies may be prescribed for MS patients for specific symptoms, such as mobility or fatigue, as a supplement to DMTs. Given that symptomatic therapies do not target the immunopathology of MS, most studies utilized MS samples of mixed phenotypes.

3.2.1 Dalfampridine

Dalfampridine (also known as fampridine or 4-aminopyridine) treats walking difficulties in persons with MS. Twelve studies investigated the cognitive efficacy of dalfampridine, five of which were RCTs: one class I, two class II, and two class III. The remaining seven studies were class IV observational studies without comparator groups. Only 5 of 12 studies investigated cognition as primary endpoints. The class I RCT was conducted with 120 cognitively impaired MS patients [48]. Significant improvement on the SDMT was observed after 12 weeks of treatment relative to placebo, with a medium effect size ($d = 0.60$). The treatment effect disappeared during a 4-week washout period after the treatment phase. A class II preliminary report of an RCT in 21 RRMS patients found significant improvement after 20 weeks of treatment compared with placebo on only 12 of 35 measures used in this study, with small to medium effect sizes on the significant measures (Cohen’s $d$ between 0.18 and 0.46) [49]. The study was limited due to the large number of outcome measures administered without specification of one or two primary outcomes, as required by the AAN criteria. In contrast, another class II RCT did not find a significant treatment effect on the SDMT after 12 weeks among 57 cognitively impaired MS patients [50]. This study was classified as class II because it did not provide sufficient information regarding its inclusion criteria and randomization. Both class III RCTs used within-subject, crossover designs. Both were class III due to a lack of equivalent treatment order groups at baseline and insufficient examination or accounting for carryover effects. One of the class III studies, the FAMPKIN extension trial, consisted of a 2-year observational period (when the whole sample received treatment) followed by a crossover RCT phase [51]. Only 20 of 32 patients from the extension trial completed the RCT phase, during which cognitive performance was superior during the dalfampridine condition compared with the placebo condition, on only one of eight measures. The other class III crossover RCT in 20 MS patients found no significant cognitive improvement during the 2-week treatment condition relative to the placebo condition [52]. Of the remaining seven class IV observational studies, six were positive [53–58].

In sum, there was one class I study in support for the cognitive efficacy of dalfampridine, with a medium effect size. For the remaining studies, higher-quality works (class II and III RCTs) yielded mixed results, while lesser quality class IV observational investigations were more likely to be positive. Thus, more work needs to be done to confirm the results of the one class I study for dalfampridine.

3.2.2 Cognition-Enhancing Medications

Cognition-enhancing medications include dementia medications (e.g., for Alzheimer’s disease) and supplements purported to improve cognitive function (e.g., Gingko biloba). Although some stimulants are used to improve cognition (e.g., for attention-deficit/hyperactivity disorder (ADHD)), they are not included in this section because they are subsumed under the category of ‘Stimulants’ in Sect. 3.2.3, along with other stimulants that are typically prescribed for wakefulness (e.g., for narcolepsy and fatigue). Nine studies on dementia medications were identified: seven studies for cholinesterase inhibitors (three for donepezil and four for rivastigmine) and two studies for memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Three studies on Gingko biloba were also included. All but three studies (two were neuroimaging studies involving rivastigmine and one examined Gingko biloba) studied cognition as primary endpoints.

Two class I RCTs and one class IV observational study examined donepezil. Both class I RCTs were conducted by the same research group, who started with a smaller single-center trial followed by a larger multicenter trial to confirm previous results. In the smaller trial among 68 mildly cognitively impaired MS patients, significant improvement was observed on the Selective Reminding Test (SRT) after 24 weeks of donepezil treatment relative to placebo with a medium effect size (Cohen’s $d = 0.49$) [59]. However, the larger RCT of 120 mildly cognitively impaired MS patients did not show a significant donepezil treatment effect compared with placebo [60], and therefore did not confirm previous results.

Four RCTs examined rivastigmine: one class I, two class II, and one class III. The class I RCT on 60 mildly cognitively impaired MS patients found no significant treatment effect, relative to placebo, on the Wechsler Memory Scale (WMS) general memory score after 12 weeks [61]. One of the class II RCTs was a small functional magnetic resonance imaging (fMRI) study with 15 MS patients [62]. Those researchers found a significant but small treatment effect on the modified PASAT after a single dose of rivastigmine compared with placebo (Cohen’s $d = 0.25$). The study was classified as class II due to the lack of specification of primary endpoints. The other class II RCT had a larger sample size with 81 cognitively impaired MS patients, but did not find a significant treatment effect for rivastigmine over placebo on the SRT after 16 weeks [63]. The last class III RCT was also an fMRI study and did not detect a significant treatment effect.
effect on the BRNB in a single (investigator)-blind, crossover design among 15 MS patients [64]. In sum, three of four RCTs (including a class I study) did not find significant cognitive treatment effects for rivastigmine among persons with MS.

One class II and one class III RCT examined memantine. Both studies used samples of mildly cognitively impaired MS patients (114 and 62, respectively) and found no significant treatment effect for memantine over placebo on the PASAT after 16 and 52 weeks [65, 66].

Two class II and one class III RCT examined *Gingko biloba*. All three studies specified more than two primary endpoints, which violated AAN class I criteria. The class II studies conducted in 38 and 120 cognitively impaired MS patients found no significant treatment effects relative to placebo after 12 weeks [67, 68]. A class III pilot RCT found medium to large treatment effects compared with placebo among 21 MS patients, on only two measures (Cohen’s $d = 0.55$ for the Visual Threshold Serial Addition Test, and $d = 0.78$ for the California Verbal Learning Test [CVLT] intrusions) out of a large number of measures (total number of measures unspecified) [69], with an inflated type I error rate.

In sum, there was consistently high-quality evidence (class I and II) that cognition-enhancing medications used for dementia (e.g. donepezil, rivastigmine, memantine) and *Gingko biloba* did not have a positive treatment effect in individuals with MS.

### 3.2.3 Stimulants

Nine studies investigated the cognitive efficacy of central nervous system stimulants: three on l-amphetamine sulfate, one on methylphenidate, one on lisdexamfetamine dimesylate, one on mixed amphetamine salts, one on armodafinil, and two on modafinil. Amphetamine-based stimulants and methylphenidate are typically prescribed to treat inattention for individuals with ADHD, and modafinil/armodafinil are used to treat fatigue in persons with MS (as well as narcolepsy). All but two studies (both for modafinil) examined cognition as the primary endpoint.

l-Amphetamine sulfate was investigated in one class I, one class II, and one class III study. In the class I RCT among 136 cognitively impaired MS patients, no significant treatment effect relative to placebo was found after 29 days, on the primary endpoint SDMT, an information processing speed measure [70]. A class II post hoc reanalysis of this trial divided patients based on baseline memory impairment (median split) [71]. Significant and large treatment effects for l-amphetamine compared with placebo were found on the CVLT-II and the Brief Visual Memory Test-Revised (BVMT-R) delayed recall scores (Cohen’s $d = 0.94$ for CVLT-II and $d = 1.00$ for BVMT-R), but only among individuals with memory impairment at baseline. In contrast, a preliminary class III crossover RCT among 19 cognitively impaired MS patients found significant medium-size treatment effects for a single dose of l-amphetamine 45 mg relative to placebo on information processing speed measures [PASAT, SDMT, and part A of the Trail-Making Test (Cohen’s $d = 0.36–0.45$)]; there was no significant change on memory measures [72]. Lower doses of l-amphetamine (15 or 30 mg) were not found to be more efficacious in improving cognitive function than placebo in this study. Still, the investigation by Benedict et al. was limited in its lack of specification of primary cognitive measures, as well as failure to examine crossover effects or baseline equivalency of treatment order groups [72]. Efficacy of a single dose of mixed amphetamine salts was investigated in a class I RCT among 49 cognitively impaired MS patients [73]. Significant improvement on the SDMT was evidenced in the treatment group relative to placebo, with a medium effect size (Cohen’s $d = 0.47$). No significant change was observed on the PASAT, the other primary endpoint. A class II RCT examined lisdexamfetamine dimesylate within a sample of 63 cognitively impaired MS patients [74]. Significant improvement on the SDMT was observed after 4 weeks of treatment up to the highest tolerable dose compared with placebo, with a medium effect size (Cohen’s $d = 0.62$). The improvement on SDMT was maintained for another 4 weeks of treatment. Again, no significant improvement was observed on the other primary endpoint, the PASAT. Of note, 76% of enrolled participants prematurely dropped out of this trial, which increased bias in the final results. A smaller class II RCT examined methylphenidate in 26 low average to cognitively impaired RRMS patients [75]. They found significant improvement on the PASAT after a single dose of the medication compared with placebo. Effect sizes were medium and large (Cohen’s $d = 0.52$ for the three-second trial and 0.71 for the two-second trial). Limited details regarding randomization and blinding were presented in this paper.

In sum, there were contradictory class I findings with regard to the cognitive efficacy of amphetamine-based formulations; two RCTs (class II and III) reported significant treatment effects. Methylphenidate and lisdexamfetamine dimesylate each had a single RCT demonstrating their efficacies (none of which were class I).

Three class II RCTs and one class III secondary analysis of a larger RCT investigated modafinil and armodafinil. The larger class II RCT conducted with 121 fatigued MS patients showed contradictory findings after 8 weeks, favoring the modafinil group on the SDMT and favoring the placebo group on the PASAT [76]. The study was limited in its lack of detailed account of blinding. Both of the smaller class II RCTs were within-subject, crossover designs and utilized samples of cognitively impaired MS patients: 30 patients...
taking armodafinil and 16 patients taking modafinil [77, 78]. Both studies found a significant treatment effect on only one of multiple measures (8 and 11, respectively); one of the significant findings was on a predefined secondary endpoint and not a primary endpoint; therefore, probabilities for type I error were high. A class III secondary analysis of a larger RCT observed a significant treatment effect [79].

3.2.4 Other Symptomatic Therapies

Amantadine is also used to treat fatigue in persons with MS. Two class III studies (one was a prospective crossover RCT and one was secondary analysis of a larger RCT) examined amantadine in 24 [80] and 45 fatigued MS patients [81]. Cognition was not the primary endpoint in either study. Neither study found significant treatment effects compared with placebo after 10 days and 6 weeks, respectively.

3.2.5 Summary

In sum, contrary to studies on DMTs, most studies on symptomatic therapies were RCTs and examined cognition as primary endpoints (see Figs. 3 and 4). They also tended to use samples of cognitively impaired patients, increasing sensitivity. Furthermore, symptomatic therapies generally yielded stronger treatment effect sizes (medium range) than DMTs (small to negligible) in RCTs that yielded positive findings (see Fig. 5). However, conclusions were difficult to draw because there were many contradictory findings in these RCTs (negative findings were not illustrated in Fig. 5). The best evidence was in dalfampridine, with one class I RCT in support of its cognitive efficacy and a medium treatment effect size. However, multiple lower-quality RCTs yielded mixed findings for dalfampridine. In contrast, there was quality evidence (class I and II) that demonstrated no significant treatment effects for cognition using dementia medications (e.g. donepezil, rivastigmine, memantine) or *Gingko biloba*. Lastly, other symptomatic therapies yielded largely mixed results in terms of their cognitive efficacy. Thus, overall, there is insufficient evidence at this time to support the use of symptomatic therapies to improve cognitive function in persons with MS.

3.3 Other Therapies

This section includes medications that are not DMTs and do not target a specific MS symptom (e.g. ambulatory disability, cognition). Cognition was not the sole primary endpoint in any of these studies. Two studies examined recombinant human erythropoietin (EPO): one class II and one class IV. The class II RCT among 50 progressive MS patients found no significant treatment effect after 24 weeks of high-dose EPO treatment on part B of the Trail-Making Test [82].
Cognitive Efficacy of MS Medications

Schreiber et al. [82] did not specify cognition as the sole primary endpoint, and it was therefore classified as class II. Two class II RCTs examined statins for 24 months and provided limited or no evidence for their cognitive efficacy. One study found significant improvement using simvastatin over placebo on one screening measure of 15 total measures among 140 secondary-progressive MS patients; primary endpoints were not specified in this study [83]. The other study did not find a significant treatment effect using atorvastatin among 154 RRMS patients; there was a high dropout rate and only 63% of enrolled participants were part of the final analyses [84]. A class II RCT compared high- and low-dose estrogen as supplemental therapy for IFN β-1a in 142 female RRMS patients [85]. After 24 months, the high-dose estrogen group (estrogen + IFN) included significantly fewer patients with cognitive impairment than the no-estrogen group (IFN only) and lower risk of developing cognitive impairment (high-dose vs. no-estrogen, odds ratio 0.27). Low-dose estrogen did not have a significant treatment effect. Classification as class II was due to the lack of a primary endpoint specification. Three studies examined methylprednisolone: one class III non-randomized, quasi-controlled study [86] and two class IV observational studies all found significant treatment effects [87, 88], but there were no class I or II studies to establish generalizable validity.

In sum, there was limited quality evidence to support the cognitive efficacy of medications reviewed in this section, and therefore insufficient evidence to support their use to improve cognitive function in persons with MS at this time.

4 Discussion

The current review aimed to systematically evaluate the cognitive efficacy of pharmacologic treatments for MS (including disease-modifying, symptomatic, and other therapies) based on papers published in peer-reviewed journals between 1990 and January 2020. Overall, none of the medications reviewed yielded consistently positive, high-quality evidence in support for their cognitive efficacy, which is in line with the most recent Cochrane review [9]. The best evidence was in dalfampridine, with one class I RCT that found a medium-sized treatment effect. However, other RCTs with dalfampridine of lower classifications yielded largely mixed findings. In contrast, there was consistently high-quality evidence (class I and II) that cognition-enhancing medications used for dementia (e.g. donepezil, rivastigmine, memantine), and *Gingko biloba*, did not have a positive treatment effect in individuals with MS. One notable finding in this review was that overall, lower-quality observational studies (i.e. class III quasi-controlled studies or class IV uncontrolled studies) tended to yield more positive findings than higher-quality studies (i.e. RCTs), as illustrated in Fig. 2. Focus on lower-quality studies may give clinicians a biased impression of the overall literature base. Furthermore, due to the scarcity of research, optimal dosage and treatment duration for the medications reviewed are unknown as existing studies vary in dosage and treatment intervals. Therefore, much work (e.g. higher-quality RCTs, comparisons of different dosages and treatment duration) is needed before formal recommendations can be made about any of the medications reviewed.

We recommend future clinical trial researchers guide their research designs using standardized criteria, such as the AAN criteria, to ensure minimization of bias. Interestingly, there was no quality evidence demonstrating cognitive efficacy for DMTs, the gold-standard treatment for MS. In fact, from our review, there were no class I studies, and class II and III studies either demonstrated no treatment effect or yielded small to negligible effect sizes. Furthermore, few good-quality studies on DMTs focused on cognition as a primary endpoint, compared with symptomatic therapies, which limited the validity and generalizability of positive findings. Additional high-quality, cognition-focused investigations of DMTs should be conducted, given the pervasiveness and insidious impact of cognitive impairment among persons with MS [1, 2, 89]. Cognition-focused investigations would allow researchers to consider cognition-related factors in study design and
analysis, and calculate power based on the cognitive outcomes. For example, to increase sensitivity for a particular cognitive treatment, it may be advantageous to recruit only cognitively impaired individuals. This was done in studies of most of the symptomatic medications (but not DMTs), as the primary goal in these studies was to evaluate cognitive benefit. Therefore, unsurprisingly, most symptomatic therapy investigations were generally higher quality (e.g. RCTs with multiple class I studies) than DMT investigations. That being said, there were many contradictory findings for symptomatic treatments. Additional inquiries into moderating treatment response variables may help explain the mixed results.

One reason for the mixed results pervasive in this review may be the heterogeneity of cognitive assessment procedures. Some studies used single primary endpoints, some used consensus batteries for MS (e.g. BRNB), and others used study-specific batteries of neuropsychological tests. Studies utilizing a battery of tests (without specification of one or two primary endpoints) may find statistically significant effects in a subset of the tests administered, and the number of significant measures may vary among studies, resulting in difficulty in interpretation (i.e. how many significant tests in a battery signify an overall positive study?). However, strictly adhering to AAN criterion of including only one or two primary endpoints (meant to reduce type I error) presents its own challenges for cognition-focused investigations. There is not a single ‘gold standard’ neuropsychological test. In fact, performance variability within a battery of neuropsychological tests occurs in even cognitively healthy individuals, with a difference of as much as six SDs between the highest and lowest scores [90]. In the MS literature, there is increasing consensus to use the SDMT as the standard primary endpoint in clinical trials [91]. Although the SDMT measures the most prevalent cognitive deficit in MS, i.e. information processing speed, it does not account for impairment in other cognitive domains, such as learning and memory or executive functions (in which impairments are also common among persons with MS). Therefore, guidelines regarding best practice in selecting primary cognitive endpoints for clinical trials, considering the aforementioned issues, is warranted. Nevertheless, future studies should prespecify primary endpoints in order to minimize type I error, in accordance with the AAN criteria.

A systemic problem identified in the current review (and research studies in general) is the overreliance on statistical significance using the $p$ value. Indeed, the present review revealed that in studies (some high in quality) that found statistically significant effects (with $p$ values below the conventional 0.05 threshold; most studies do not adjust for multiple comparisons), some studies yielded small or even negligible effect sizes (Cohen’s $d < 0.20$). Overreliance on the $p$ value has been cited as one of the reasons for the reproducibility crisis. Furthermore, a statement from the American Statistical Association stressed that the $p$ value does not measure the size of an effect or the significance of a finding [92]. Instead, statisticians recommend using effect sizes, and confidence intervals around the effect sizes, to denote the significance of a result [93, 94]. Therefore, when evaluating whether to prescribe a certain medication to improve cognitive function in MS patients based on published findings, clinicians are urged to consider the effect sizes and confidence intervals rather than reliance on the $p$ values.

The current review offers unique strengths compared with past reviews on the same topic. The inclusion of a standardized effect size measure provides an objective metric that can be compared across studies. The use of evidence classification helps to account for potential sources of bias in the studies reviewed. However, a few limitations have to be addressed. We only calculated effect sizes for positive findings in controlled studies. It is possible that some negative studies have strong effect sizes but did not reach statistical significance due to small sample sizes. We decided to not calculate effect sizes for negative findings because one could argue that small sample sizes may not be representative samples of the population being investigated. Nevertheless, we note this as a limitation, as it may underestimate the overall effects observed in the literature. Furthermore, we were unable to calculate effect sizes for some studies due to insufficient data, such as missing means and SDs. Due to these missing data, along with variability in the study endpoints, we were unable to conduct a quantitative meta-analysis. Another limitation of our effect size calculations is the treatment of all available data as a parametric. Although some studies utilized non-parametric tests for their main analyses, the majority did not provide the relevant statistics for which effect sizes could be calculated. Thus, we used the provided means and SDs to calculate Cohen’s $d$. Lastly, we did not account for correlations between repeated measurements in our effect size calculations because most studies did not provide this information.

5 Conclusions

According to the current systematic review, there is insufficient evidence to support the use of pharmacologic treatments to improve cognitive function in persons with MS. There were many contradictory findings observed in this review, which may be due to possible unidentified moderating treatment response variables and/or lack of standardization in assessment procedures. Higher-quality RCTs with cognition as the primary outcome are needed to establish the cognitive efficacy of pharmacologic treatments for MS-related cognitive dysfunction. Future clinical trial researchers are urged to utilize standardized criteria (such as the
AAN criteria) to guide their study designs. There was also an overreliance on statistical significance in determining the overall cognitive efficacy of a medication, which may not be clinically meaningful. Clinicians should consider effect sizes of medications before deciding whether to prescribe them to ameliorate cognitive symptoms.

Compliance with Ethical Standards

Funding The preparation of this manuscript was supported in part by National Multiple Sclerosis Society Grant MB-1606-08779 to John DeLuca, NMSS Grant CA1069-A-7 to John DeLuca, and the Kessler Foundation. Open access publishing was paid for by Kessler Foundation.

Conflict of interest Helen M. Genova has received funding from the National Multiple Sclerosis Society. John DeLuca has received funding from the National Multiple Sclerosis Society; served as a consultant or member of the advisory board for Biogen, Celgene, Novartis, and MedRhythms; provided paid lectures for Biogen and Sanoft-Genzyme; and received book royalties. Michelle H. Chen and Yael Goverover declare no potential conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Lovera J, Kovner B. Cognitive impairment in multiple sclerosis. Curr Neurol Neurosci Rep. 2012;12(5):618–27.
2. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.
3. Langdon D. Cognition in multiple sclerosis. Curr Opin Neurol. 2011;24(3):244–9.
4. Goverover Y, Chiaravalloti ND, DeLuca J. Money management in multiple sclerosis: the role of cognitive, motor and affective factors. Front Neurol. 2019;10:1128.
5. Strober LB, Christodoulou C, Benedict RH, Westervelt HJ, Melville P, Scherl WF, et al. Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler J. 2012;18(5):647–53.
6. Imusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasanagendra V, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler J. 2010;16(12):1414–21.
7. Filippi M, Horsfield M, Tofts P, Barkhof F, Thompson A, Miller D. Qualitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 1995;118(6):1601–12.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444.
9. He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev. 2013;12:CD008876.
10. Roy S, Benedict RH, Drake AS, Weinstock-Guttman B. Impact of pharmacotherapy on cognitive dysfunction in patients with multiple sclerosis. CNS Drugs. 2016;30(3):209–25.
11. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Information processing speed in multiple sclerosis: past, present, and future. Mult Scler J. 2017;23(6):772–89.
12. Gronseth GS, Cox J, Gloss D, Merillat S, Dittman J, Armstrong MJ, et al. 2017 Edition clinical practice guideline process manual. American Academy of Neurology; 2017.
13. Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods. 2008;11(2):364–86.
14. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7(1):105.
15. Mokhber N, Azarpazhooh A, Oriuji E, Rao SM, Khorram B, Sahraian MA, et al. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci. 2014;342(1–2):16–20.
16. Melanson M, Grossberndt A, Kwokaw M, Leong C, Frost EE, Prout M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. Int J Neurosci. 2010;120(10):631–40.
17. Cohen J, Cutter G, Fischer J, Goodman A, Heidenreich F, Kooijmans M, et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5):679–87.
18. Fischer JS, Priole RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Ann Neurol. 2000;48(6):885–92.
19. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, et al. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing–remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLOS One. 2013;8(8):e74111.
20. Patti F, Amato M, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing–remitting multiple sclerosis. Mult Scler J. 2010;16(1):68–77.
21. Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich F, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler J. 2009;15(10):1195–205.
22. Penner I-K, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler J. 2012;18(10):1466–71.
23. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol. 2002;47(1):11–4.
24. Pliskin N, Hamer D, Goldstein D, Towle V, Reder A, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996;47(6):1463–8.
25. Fletcher S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J. 2007;9(6):457–9.
26. Weinstein A, Schwid SI, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999;56(3):319–24.
27. Vacaras V, Major ZZ, Seewooram R, Major KA, Muresanu DF, Buzoianu AD. Disease activity and disability evolution under...
glatiramer acetate: a clinical approach. Neuropsychopharmacol Hung. 2014;16(1):11–8.

28. Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist L, et al. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand. 2007;116(2):96–9.

29. Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, et al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol. 2014;261(11):2101–11.

30. Ziemssen T, Calabrese P, Penner I-K, Apfel R. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients. J Neurol. 2016;263(4):784–91.

31. Ziemssen T, Gilgun-Sherki Y. Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate. BMC Neurol. 2015;15(1):189.

32. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Mattioli F, Stampatori C, Bellomi F, Capra R. The effect of natalizumab on cognitive functioning following one-year natalizumab treatment: a non-randomized clinical trial. Acta Neurol Scand. 2012;125(5):898–905.

33. Collie A, Maruff P, Makiyosi M, McStephen M, Darby DG, McCrory P. Statistical procedures for determining the extent of cognitive change following concussion. Br J Sports Med. 2011;45(9):658–66.

34. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32(1):83–8.

35. Rorsman I, Petersen C, Nilsson P. Cognitive functioning following one-year natalizumab treatment: a non-randomized clinical trial. Acta Neurol Scand. 2018;137(1):117–24.

36. Iaffaldano P, Viterbo RG, Trojano M. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. J Neurol. 2016;263(8):1620–5.

37. Mattioli F, Stampatori C, Bellomi F, Capra R. Natalizumab efficacy on cognitive impairment in MS. Neurol Sci. 2011;31(3):321–3.

38. Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M. The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis. Brain Behav Immun. 2014;35:176–81.

39. Lang C, Reiss C, Müürer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol. 2012;67(3):162–6.

40. Novakova L, Axelsson M, Malmeström C, Zetterberg H, Björkhem I, Karrenbauer VD, et al. Reduced cerebrospinal fluid concentrations of oxytocin in response to natalizumab treatment of relapsing remitting multiple sclerosis. J Neurol Sci. 2015;358(1–2):201–6.

41. Wilken J, Kane RL, Sullivan CL, Gudesblatt M, Lucas S, Falls R, et al. Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab: the ENER-G study. Int J MS Care. 2013;15(3):120–8.

42. Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, et al. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. BMC Neurol. 2019;19(1):116.

43. Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Gorette B, et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One. 2012;7(4):e35843.
60. Krupp L, Christodoulou C, Melville P, Scherl W, Pai L-Y, Muenz L, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76(17):1500–7.

61. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakzade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476–81.

62. Huolman S, Hämäläinen P, Vorobyev V, Ruutuainen J, Parkkola R, Laine T, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler J. 2011;17(11):1351–61.

63. Mäurer M, Ortler S, Baier M, Meerangs M, Scherer P, Hofmann W, et al. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler J. 2013;19(5):631–8.

64. Cader S, Palace J, Matthews P. Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis. J Psychopharmacol. 2009;23(6):686–96.

65. Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler J. 2010;16(6):715–23.

66. Saint Paul LP, Creveuil C, Heinzlef O, De Seje Z, Verraschi P, Castelnovo G, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69–76.

67. Lovera J, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner A, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology. 2012;79(12):1278–84.

68. Lovera J, Bagert B, Smoot K, Morris C, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive function in patients with multiple sclerosis. J Neurol Sci. 2007;256(4):645–50.

69. Diamond BJ, Johnson SK, Kaufman M, Shifflett SC, Graves L. A randomized controlled pilot trial: the effects of EGB 761 on information processing and executive function in multiple sclerosis. Explore (NY). 2013;9(2):106–7.

70. Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, et al. The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(1–2):38–40.

71. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakzade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476–81.

72. Huolman S, Hämäläinen P, Vorobyev V, Ruutuainen J, Parkkola R, Laine T, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler J. 2011;17(11):1351–61.

73. Mäurer M, Ortler S, Baier M, Meerangs M, Scherer P, Hofmann W, et al. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler J. 2013;19(5):631–8.

74. Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler J. 2010;16(6):715–23.

75. Saint Paul LP, Creveuil C, Heinzlef O, De Seje Z, Verraschi P, Castelnovo G, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69–76.

76. Lovera J, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner A, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology. 2012;79(12):1278–84.

77. Lovera J, Bagert B, Smoot K, Morris C, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive function in patients with multiple sclerosis. J Neurol Sci. 2007;256(4):645–50.

78. Lovera J, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner A, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology. 2012;79(12):1278–84.

79. Lovera J, Frohman E, Brown T, Bandari D, Nguyen L, Yadav V, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler J. 2010;16(6):715–23.

80. Saint Paul LP, Creveuil C, Heinzlef O, De Seje Z, Verraschi P, Castelnovo G, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69–76.

81. Lovera J, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner A, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. Neurology. 2012;79(12):1278–84.

82. Lovera J, Bagert B, Smoot K, Morris C, Frank R, Bogardus K, et al. Ginkgo biloba for the improvement of cognitive function in patients with multiple sclerosis. J Neurol Sci. 2007;256(4):645–50.
92. Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129–33.
93. Van Calster B, Steyerberg EW, Collins GS, Smits T. Consequences of relying on statistical significance: some illustrations. Eur J Clin Investig. 2018;48(5):e12912.
94. Smith EP. Ending reliance on statistical significance will improve environmental inference and communication. Estuaries Coasts. 2020;43:1–6.
95. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain. 2007;130(10):2577–88.
96. Selby MJ, Ling N, Williams JM, Dawson A. Interferon beta 1-b in verbal memory functioning of patients with relapsing–remitting multiple sclerosis. Percept Motor Skills. 1998;86(3):1099–106.
97. Sundgren M, Piel F, Wahlin Å, Brismar T. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study. Mult Scler Relat Disord. 2016;10:36–43.
98. Schröder A, Klotz P, Lee D-H, Gold R, Linker RA. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Clin Neurol Neurosurg. 2011;113(7):527–30.
99. Edan G, Kappos L, Montalban X, Polman C, Freedman M, Hartung H-P, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. 2014;85(11):1183–9.
100. Kappos L, Edan G, Freedman MS, Montalban X, Hartung H-P, Hemmer B, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87(10):978–87.
101. Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, et al. Interferon beta-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol. 2011;68(11):1421–7.
102. Gerschlager W, Beisteiner R, Deecke L, Dirnberger G, Endl W, Kollegger H, et al. Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon β-1b: a 1-year follow-up. Eur Neurol. 2000;44(4):205–9.
103. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler J. 2013;19(13):1765–72.
104. Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP, CS Group. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007;255(1–2):57–63.
105. Coyle PK, Khatri B, Edwards KR, Mecca-Lallana JE, Cavalier S, Ruﬁ P, et al. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study. Mult Scler Relat Disord. 2017;17:107–15.
106. Fox E, Sullivan H, Gazda S, Mayer L, O’Donnell L, Melia K, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19(2):307–11.
107. Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35–40.
108. Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol. 2000;20(3):350–6.